No Data
No Data
Xintiandi (301277.SZ): Pharmaceutical production license changes mainly involve increasing commissioned production
Gelonghui, May 21丨Xintiandi (301277.SZ) announced that the company (hereinafter referred to as the “Company”) recently obtained a “Pharmaceutical Production License” issued by the Henan Drug Administration and agreed to the “Pharmaceutical Production License” change application. This change mainly involves an increase in contract production; other details remain unchanged. Additional commissioned items: Trustee Company: Baizheng Pharmaceutical Co., Ltd.; Commissioned Variety: Moxifloxacin Hydrochloride Tablets (Specification: 0.4g); Commissioned Production Address: No. 3888 Xuyou East Road, Dongcheng District, Xuchang City; Commissioned Production Workshop and Production Line: Tablet Workshop, General Production Line. (Pharmaceuticals only
Xintian Real Estate Group (00760.HK) proposes share capital restructuring
Gelonghui, May 10, 丨 Xintian Real Estate Group (00760.HK) announced that the company proposes to carry out and implement a share capital restructuring, which will involve the following steps: (a) share capital reduction, which will involve reducing the company's issued share capital by canceling HK$0.07 per issued share to reduce the company's issued share capital, so that the face value of each issued share will be reduced from HK$0.08 to HK$0.01; (b) pending and immediately after the share capital reduction, the shares will be split. Unissued shares with a face value of HK$0.08 per share were split into 8 shares per share Face value 0.0
Xintiandi (301277.SZ): No technological achievements have been formed in synthetic biotechnology that can be industrialized
Gelonghui, May 7 | Xintiandi (301277.SZ) said on the investor interactive platform that up to now, the company has not achieved technological achievements that can be industrialized in synthetic biotechnology.
Newland Pharmaceutical Co., Ltd. (SZSE:301277) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Newland Pharmaceutical Co., Ltd. (SZSE:301277) is about to trade ex-dividend in the next three
Xintiandi (301277.SZ): Net profit of 559.181,000 yuan in the first quarter increased 19.69% year-on-year
Gelonghui, April 23 | Xintiandi (301277.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 185 million yuan, up 6.98% year on year; net profit attributable to shareholders of listed companies was 559.181,000 yuan, up 19.69% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 52,2691,000 yuan, up 22.37% year on year; basic earnings per share were 0.28 yuan.
Coastal Homes subsidiary signs share transfer agreement with Liang Xiaodong
Coastal Homes (01124) issued an announcement. On March 27, 2024, the seller Fengying Global Investment Co., Ltd. (a wholly-owned subsidiary of the company) signed a share transfer agreement with the buyer Liang Xiaodong. The seller has agreed to sell shares conditionally, and the buyer has agreed to buy and sell shares at a total cost of HK$10,000 in accordance with the terms of the share transfer agreement (equivalent to the total number of issued shares of the company sold). According to reports, the selling company Qifeng Development Co., Ltd. was an indirect wholly-owned subsidiary of the company on the date of this announcement and immediately before completion. The selling company is mainly engaged in investment holding, and its subsidiaries are mainly engaged in property development and investment control
No Data